# Efficacy and Safety of Clesrovimab (MK-1654) in Infants (MK-1654-004)

> **NCT04767373** · PHASE2,PHASE3 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 3632 (actual)

## Conditions studied

- Respiratory Syncytial Virus Infection

## Interventions

- **BIOLOGICAL:** Clesrovimab
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04767373
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-04-07
- **Primary completion:** 2024-07-09
- **Final completion:** 2024-07-09
- **Target enrollment:** 3632 (ACTUAL)
- **Last updated:** 2026-02-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04767373

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04767373, "Efficacy and Safety of Clesrovimab (MK-1654) in Infants (MK-1654-004)". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT04767373. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*